Natalie R. Sacks M.D.
Net Worth

Last updated:

What is Natalie R. Sacks M.D. net worth?

The estimated net worth of Dr. Natalie R. Sacks M.D. is at least $3,816,717 as of 18 May 2020. He has earned $16,617 from insider trading and has received compensation worth at least $3,800,100 in Harpoon Therapeutics, Inc..

What is the salary of Natalie R. Sacks M.D.?

Dr. Natalie R. Sacks M.D. salary is $633,350 per year as Chief Medical Offer in Harpoon Therapeutics, Inc..

How old is Natalie R. Sacks M.D.?

Dr. Natalie R. Sacks M.D. is 60 years old, born in 1965.

What stocks does Natalie R. Sacks M.D. currently own?

As insider, Dr. Natalie R. Sacks M.D. owns shares in one company:

Company Title Shares Price per share Total value
Harpoon Therapeutics, Inc. (HARP) Chief Medical Offer 45,754 $0 $0

What does Harpoon Therapeutics, Inc. do?

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

HARP logo
HARP
Harpoon Therapeutics, Inc.

Natalie R. Sacks M.D. insider trading

Harpoon Therapeutics, Inc.

Dr. Natalie R. Sacks M.D. has made 20 insider trades between 2019-2020, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 18,252 units of HARP stock on 18 Nov 2019. As of 18 May 2020 he still owns at least 45,754 units of HARP stock.

Transaction Date Security Shares Price per share Total value Source
Option
Employee Stock Option (right to buy) 1,522 $2.12 $3,227
Sale
Common Stock 1,522 $2.12 $3,227
Option
Common Stock 1,522 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Common Stock 5,826 $2.12 $12,351
Option
Employee Stock Option (right to buy) 5,826 $2.12 $12,351
Option
Employee Stock Option (right to buy) 1,021 $12.08 $12,331
Option
Common Stock 1,021 $12.08 $12,331
Sale
Common Stock 1,021 $12.08 $12,331
Option
Employee Stock Option (right to buy) 500 $2.12 $1,060
Option
Common Stock 500 N/A N/A
Sale
Common Stock 500 $2.12 $1,060
Sale
Common Stock 4,556 N/A N/A
Option
Common Stock 4,556 N/A N/A
Option
Employee Stock Option (right to buy) 4,556 N/A N/A
Option
Employee Stock Option (right to buy) 570 N/A N/A
Option
Common Stock 570 N/A N/A
Sale
Common Stock 570 N/A N/A
Option
Employee Stock Option (right to buy) 700 N/A N/A
Sale
Common Stock 700 N/A N/A
Option
Common Stock 700 N/A N/A
Option
Employee Stock Option (right to buy) 1,520 N/A N/A
Option
Common Stock 1,520 N/A N/A
Sale
Common Stock 1,520 N/A N/A
Option
Employee Stock Option (right to buy) 1 N/A N/A
Option
Common Stock 1 N/A N/A
Sale
Common Stock 1 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 1,521 N/A N/A
Option
Common Stock 1,521 N/A N/A
Sale
Common Stock 1,521 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 5,826 N/A N/A
Option
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 1,521 N/A N/A
Option
Common Stock 1,521 N/A N/A
Sale
Common Stock 1,521 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 5,826 N/A N/A
Option
Common Stock 1,521 N/A N/A
Option
Employee Stock Option (right to buy) 1,521 N/A N/A
Sale
Common Stock 1,521 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 18,252 N/A N/A
Sale
Common Stock 18,252 N/A N/A
Option
Common Stock 18,252 N/A N/A
Option
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 5,826 N/A N/A
Sale
Common Stock 5,826 N/A N/A
Option
Employee Stock Option (right to buy) 11,698 N/A N/A
Sale
Common Stock 11,698 N/A N/A
Option
Common Stock 11,698 N/A N/A
Option
Common Stock 12,452 N/A N/A
Sale
Common Stock 12,452 N/A N/A
Option
Employee Stock Option (right to buy) 12,452 N/A N/A

Harpoon Therapeutics key executives

Harpoon Therapeutics, Inc. executives and other stock owners filed with the SEC: